Purpose of this Study
We are doing this study to see if blood and bone marrow samples can be tested in a timely manner that allows for the detection of certain markers that could guide cancer treatment.
Who Can Participate?
Eligibility
Adults ages 18+ who:<ul>
<li>Are suspected to have previously untreated AML or MDS (paarticipants with AML cannot have a history of previously treated myeloproliferative neoplasms)</li>
<li>Have not received prior anti-cancer therapy for AML or MDS (previous erythroid stimulating agent is not considered prior therapy for the purposes of eligibility)</li></ul>
For more information about this study, please contact the study team at <a href="mailto: marty.c.cauley@duke.edu">marty.c.cauley@duke.edu.</a>
<li>Are suspected to have previously untreated AML or MDS (paarticipants with AML cannot have a history of previously treated myeloproliferative neoplasms)</li>
<li>Have not received prior anti-cancer therapy for AML or MDS (previous erythroid stimulating agent is not considered prior therapy for the purposes of eligibility)</li></ul>
For more information about this study, please contact the study team at <a href="mailto: marty.c.cauley@duke.edu">marty.c.cauley@duke.edu.</a>
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Looking for Healthy Participants
No
What is Involved?
If you choose to join this study, you will have blood draws and bone marrow samples taken for testing.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
Yes
Study Details
Full Title
MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials
Principal Investigator
Harry
Erba
Protocol Number
PRO00116097
NCT ID
NCT05564390
Enrollment Status
Pending Open to Enrollment